Skip to main content

Table 3 PubMed and PMC searches for OI-MET-TF genes and cancer, BC, PC, and MET

From: A bioinformatics approach reveals novel interactions of the OVOL transcription factors in the regulation of epithelial – mesenchymal cell reprogramming and cancer progression

For 52 OI-MET-TF genes, number found in: PubMed queries for % PubMed p-value PMC queries for % PMC p-value
(“cancer”[ Text Word] +  OR + “ neoplasms ”[Text Word]) 45 86.5% < 0.01 48 92.3% < 0.01
(“breast cancer”[ Text Word] +  OR + “ breast neoplasms”[ Text Word]) 47 90.4% < 0.01 49 94.2% < 0.01
(“prostate cancer”[ Text Word] +  OR + “ prostate neoplasms”[ Text Word]) 36 69.2% < 0.01 48 92.3% < 0.01
(“epithelial- mesenchymal transition ”[MeSH Terms]) 21 40.4% < 0.0001 38 73.1% < 0.0001
For All 36, 973 HGNC Genes, Number found in: PubMed queries for    PMC queries for % PMC  
(“epithelial- mesenchymal transition”[ MeSH Terms]) 995 2.7%   1669 4.5%  
  1. As with the OI-MET gene set “cancer”, “breast cancer”, and “prostate cancer” text word searches show that a high proportion of OI-MET-TF genes are associated with these concepts in the literature. For all six tests the empirical p-value is < 0.01. “Epithelial-mesenchymal transition” MeSH term searches show an even more significant enrichment of this annotation in the OI-MET set, relative to all genes: 40.4% ÷ 2.7% = 15.2 Fold Enrichment for PubMed; 73.1% ÷ 4.5% = 16.4 Fold Enrichment for PMC; both with p-value < 0.0001.